Search results for "CELL TRANSPLANTATION"

showing 10 items of 493 documents

Therapy-related acute myeloid leukemia developing 14 years after allogeneic hematopoietic stem cell transplantation, from a persistent R882H- DNMT3A …

2018

Abstract Background Therapy-related acute myeloid leukemia (t-AML) develops in patients with prior exposure to cytotoxic therapies. Selection of a pre-existing TP53 mutated clone prone to acquire additional mutational events has been suggested as the main pathogenic mechanism of t-AML. Here, we report a unique case of t-AML which developed from a pre-existing DNMT3A mutated clone that persisted in the patient for more than 10 years despite treatment with intensive chemotherapy and allogeneic hematopoietic stem cell transplantation (alloHSCT). Case presentation A 42-year-old male was diagnosed with AML harboring a normal karyotype and mutations in the NPM1 (c.863_864ins, p.W288 fs*12), DNMT3…

AdultMaleOncologymedicine.medical_specialtyNPM1Allogeneic transplantationmedicine.medical_treatmentClinical BiochemistryMutation MissenseClone (cell biology)Therapy-Related Acute Myeloid LeukemiaHematopoietic stem cell transplantationDNA Methyltransferase 3APathology and Forensic Medicine03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansTransplantation HomologousDNA (Cytosine-5-)-MethyltransferasesMolecular BiologyBone Marrow Transplantationbusiness.industryMyeloid leukemiaInduction chemotherapyTransplantationLeukemia Myeloid Acute030220 oncology & carcinogenesisbusinessNucleophosmin030215 immunologyExperimental and Molecular Pathology
researchProduct

Pre-Emptive Immunotherapy for Clearance of Molecular Disease in Childhood Acute Lymphoblastic Leukemia after Transplantation

2016

Abstract Monitoring of minimal residual disease (MRD) or chimerism may help guide pre-emptive immunotherapy (IT) with a view to preventing relapse in childhood acute lymphoblastic leukemia (ALL) after transplantation. Patients with ALL who consecutively underwent transplantation in Frankfurt/Main, Germany between January 1, 2005 and July 1, 2014 were included in this retrospective study. Chimerism monitoring was performed in all, and MRD assessment was performed in 58 of 89 patients. IT was guided in 19 of 24 patients with mixed chimerism (MC) and MRD and by MRD only in another 4 patients with complete chimerism (CC). The 3-year probabilities of event-free survival (EFS) were .69 ± .06 for …

AdultMaleOncologymedicine.medical_specialtyNeoplasm ResidualAdolescentmedicine.medical_treatmenteducationDiseaseRelapse preventionChimerismYoung Adult03 medical and health sciences0302 clinical medicineRecurrenceGermanyInternal medicineSecondary PreventionHumansTransplantation HomologousMedicineddc:610ChildChildhood Acute Lymphoblastic LeukemiaImmunosuppression TherapyTransplantationbusiness.industryHematopoietic Stem Cell TransplantationRetrospective cohort studyHematologyImmunotherapyPrecursor Cell Lymphoblastic Leukemia-LymphomaSurvival AnalysisMinimal residual diseaseSurgeryTransplantationChild PreschoolLymphocyte Transfusion030220 oncology & carcinogenesisCohortFemaleImmunotherapybusiness030215 immunologyBiology of Blood and Marrow Transplantation
researchProduct

Effect of Sirolimus Exposure on the Need for Preemptive Antiviral Therapy for Cytomeglovirus Infection after Allogeneic Hematopoietic Stem Cell Trans…

2019

The current study evaluates the clinical effect of sirolimus exposure on the occurrence of cytomegalovirus (CMV) DNAemia necessitating preemptive antiviral therapy. A total of 167 consecutive recipients of reduced-intensity conditioning (RIC) allogeneic hematopoietic stem cell transplantation (allo-HSCT) who received sirolimus- and tacrolimus-based graft-versus-host disease (GVHD) prophylaxis and whose CMV serostatus was positive for donors and/or recipients were included in this multicenter retrospective study. A parametric model with consecutive sirolimus blood levels describing the time to CMV DNAemia-RAT was developed using NONMEM version 7.4. Overall, 122 of 167 patients (73%) were all…

AdultMaleOncologymedicine.medical_specialtyPremedicationmedicine.medical_treatmentCongenital cytomegalovirus infectionHematopoietic stem cell transplantationAntiviral AgentsAllogeneic hematopoietic stem cells transplantationMechanistic target of rapamycin inhibitorQuantitative PCR03 medical and health sciences0302 clinical medicineTime-to-event analysisInternal medicineHumansTransplantation HomologousMedicineCumulative incidenceCytomegalovirus diseaseSurvival analysisRetrospective StudiesSirolimusTransplantationDose-Response Relationship Drugbusiness.industryHazard ratioHematopoietic Stem Cell TransplantationPK/PDvirus diseasesRetrospective cohort studyHematologyMiddle Agedmedicine.diseaseCytomegalovirus infectionsurgical procedures operativeCytomegalovirus DNAemia030220 oncology & carcinogenesisSirolimusCytomegalovirus InfectionsPreemptive antiviral therapySirolimus exposureFemalebusinessSerostatusImmunosuppressive Agents030215 immunologymedicine.drug
researchProduct

Improved relapse-free survival after autologous stem cell transplantation does not translate into better quality of life in chronic lymphocytic leuke…

2014

Item does not contain fulltext In chronic lymphocytic leukemia (CLL) medical progress is driven by clinical studies with relapse-free survival (RFS) as the primary endpoint. The randomized EBMT-Intergroup trial compared high-dose therapy and autologous stem cell transplantation (ASCT) to observation and demonstrated a substantial improvement of RFS without showing improved overall survival for the transplant arm. Here we report quality of life (QoL) information of the first 3 years following randomization from that study. The main objective was to assess the impact of treatment on QoL over time. Two secondary analyses were performed to further investigate the impact of ASCT and relapse on Q…

AdultMaleOncologymedicine.medical_specialtyTransplantation ConditioningRandomizationCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2][SDV]Life Sciences [q-bio]medicine.medical_treatmentChronic lymphocytic leukemiaHematopoietic stem cell transplantationTransplantation Autologous03 medical and health sciences0302 clinical medicineAutologous stem-cell transplantationQuality of lifeRecurrenceSurveys and QuestionnairesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumansComputingMilieux_MISCELLANEOUSAgedbusiness.industryHematopoietic Stem Cell TransplantationHematologyMiddle Agedmedicine.diseaseLeukemia Lymphocytic Chronic B-Cellhumanities3. Good healthSurgeryTransplantation030220 oncology & carcinogenesisQuality of LifeFemaleTransplantation Conditioningbusiness030215 immunologyAmerican Journal of Hematology
researchProduct

Relative Impact of HLA Matching and Non-HLA Donor Characteristics on Outcomes of Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and …

2018

Increasing donor-recipient HLA disparity is associated with negative outcomes of allogeneic hematopoietic stem cell transplantation (HSCT), but its comparative relevance amid non-HLA donor characteristics is not well established. We addressed this question in 3215 HSCTs performed between 2005 and 2013 in Germany for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Donors were HLA-matched related (MRD; n = 872) or unrelated (10/10 MUD, n = 1553) or HLA-mismatched unrelated (10/10 MMUD, n = 790). Overall survival (OS) was similar after MRD compared with 10/10 MUD HSCT, reflecting opposing hazards of relapse (hazard ratio [HR], 1.32; P.002) and nonrelapse mortality (HR, .63; P.0…

AdultMaleOncologymedicine.medical_specialtymedicine.medical_treatmentMedizinHematopoietic stem cell transplantationHuman leukocyte antigenDonor age03 medical and health sciences0302 clinical medicineRecurrenceInternal medicinemedicineHumansTransplantation HomologousTransplantationbusiness.industryHematopoietic Stem Cell TransplantationMyeloid leukemiaHematologyMiddle AgedTissue DonorsTransplantationLeukemia Myeloid AcuteTreatment OutcomeMale patientMyelodysplastic Syndromes030220 oncology & carcinogenesisAllogeneic hsctFemaleStem cellbusiness030215 immunologyBiology of Blood and Marrow Transplantation
researchProduct

Human Dental Pulp Stem Cells Improve Left Ventricular Function, Induce Angiogenesis, and Reduce Infarct Size in Rats with Acute Myocardial Infarction

2008

Abstract Human dental pulp contains precursor cells termed dental pulp stem cells (DPSC) that show self-renewal and multilineage differentiation and also secrete multiple proangiogenic and antiapoptotic factors. To examine whether these cells could have therapeutic potential in the repair of myocardial infarction (MI), DPSC were infected with a retrovirus encoding the green fluorescent protein (GFP) and expanded ex vivo. Seven days after induction of myocardial infarction by coronary artery ligation, 1.5 × 106 GFP-DPSC were injected intramyocardially in nude rats. At 4 weeks, cell-treated animals showed an improvement in cardiac function, observed by percentage changes in anterior wall thic…

AdultMalePathologymedicine.medical_specialtyAdolescentAngiogenesismedicine.medical_treatmentMyocytes Smooth MuscleCell- and Tissue-Based TherapyMyocardial InfarctionNeovascularization PhysiologicBiologystem cell therapyventricular remodelingVentricular Function LeftRats Nudeleft ventricular functionDental pulp stem cellsmedicineAnimalsHumansMyocytes CardiacMyocardial infarctionVentricular remodelingDental PulpCell ProliferationUltrasonographymesenchymal stem cellsStem CellsCardiac muscleCell DifferentiationMesenchymal Stem CellsAmniotic stem cellsCell BiologyStem-cell therapyAnatomymedicine.diseasedental pulp stem cellsRatsRetroviridaemedicine.anatomical_structureMolecular MedicineStem cellRetroviridae InfectionsStem Cell TransplantationDevelopmental BiologyStem Cells
researchProduct

Significance of increased blastic-appearing cells in bone marrow following myeloablative unrelated cord blood transplantation in adult patients.

2012

An abnormal increase of nonleukemic blastic-appearing lymphocytes in bone marrow (BM) specimens has been reported after unrelated cord blood transplantation (UCBT). This study analyzed the incidence, chronology, biological features, and clinical significance of elevated numbers of these cells in a series of 165 consecutive adult patients demonstrating myeloid engraftment after myeloablative UCBT in a single institution. The patients' BM samples were routinely evaluated by cytomorphology at different time points after UCBT. When ≥5% of blastic-appearing cells were detected by cytomorphology in the BM, samples were also evaluated by multiparametric flow cytometry to characterize these cells. …

AdultMalePathologymedicine.medical_specialtyAllogeneic Hematopoietic stem Cell TransplantMyeloidBone Marrow CellsTransplantation ChimeraCord Blood Stem Cell TransplantationHematogonesFlow cytometryInmune ReconstitutionBone MarrowmedicineHumansClinical significanceCumulative incidenceLymphocyte CountTransplantationTransplantation Chimeramedicine.diagnostic_testbusiness.industryIncidence (epidemiology)HematologyFetal BloodPrognosismedicine.anatomical_structureFemaleBone marrowCord Blood Stem Cell TransplantationbusinessBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
researchProduct

Bone Marrow-Derived Cells from Male Donors Do Not Contribute to the Endometrial Side Population of the Recipient

2012

Accumulated evidence demonstrates the existence of bone marrow-derived cells origin in the endometria of women undergoing bone marrow transplantation (BMT). In these reports, cells of a bone marrow (BM) origin are able to differentiate into endometrial cells, although their contribution to endometrial regeneration is not yet clear. We have previously demonstrated the functional relevance of side population (SP) cells as the endogenous source of somatic stem cells (SSC) in the human endometrium. The present work aims to understand the presence and contribution of bone marrow-derived cells to the endometrium and the endometrial SP population of women who received BMT from male donors. Five fe…

AdultMalePathologymedicine.medical_specialtyStromal cellClinical Research DesignCellular differentiationmedicine.medical_treatmentSciencePopulationImmunologyFluorescent Antibody TechniqueBone Marrow CellsHematopoietic stem cell transplantationBiologyTetraspanin 29AndrologyEndometriumEndocrinologySide populationDiagnostic MedicineMolecular Cell BiologymedicineHumansVimentineducationBiologyIn Situ Hybridization FluorescenceBone Marrow Transplantationeducation.field_of_studyMultidisciplinaryQRObstetrics and GynecologyTissue Donorsmedicine.anatomical_structureMedicineWomen's HealthLeukocyte Common AntigensFemaleBone marrowStem cellCellular TypesCytometryAdult stem cellResearch ArticlePLoS ONE
researchProduct

Functional profile of cytomegalovirus (CMV)-specific CD8+ T cells and kinetics of NKG2C+ NK Cells associated with the resolution of CMV DNAemia in al…

2011

Immune mechanisms involved in control of cytomegalovirus (CMV) infection in the allogeneic stem cell transplantation setting have not been fully disclosed. CMV pp65 and IE-1-specific CD8(+) T cells expressing IFN-γ, TNF-α, and CD107a, alone or in combination, and NKG2C(+) NK cells were prospectively enumerated during 13 episodes of CMV DNAemia. The expansion of monofunctional and polyfunctional CD8(+) T cells was associated with CMV DNAemia clearance. The size and functional diversity of the expanding CD8(+) T-cell population was greater in self-resolved episodes than in episodes treated with antivirals. These differences were related to the magnitude of expansion of cognate antigen IFN-γ C…

AdultMalePopulationCongenital cytomegalovirus infectionCytomegalovirusCD8-Positive T-LymphocytesBiologyViral Matrix ProteinsInterferon-gammaYoung AdultInterleukin 21AntigenLysosomal-Associated Membrane Protein 1VirologymedicineHumansTransplantation HomologousCytotoxic T celleducationeducation.field_of_studyTumor Necrosis Factor-alphaReceptors IgGvirus diseasesMiddle AgedPhosphoproteinsmedicine.diseaseVirologyCD56 AntigenKiller Cells NaturalTransplantationInfectious DiseasesCytomegalovirus InfectionsDNA ViralImmunologyFemaleStem cellNK Cell Lectin-Like Receptor Subfamily CCD8Stem Cell TransplantationJournal of Medical Virology
researchProduct

Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host Disease

2007

Invasive fungal infections are an important cause of morbidity and mortality after allogeneic hematopoietic stem-cell transplantation.In an international, randomized, double-blind trial, we compared oral posaconazole with oral fluconazole for prophylaxis against invasive fungal infections in patients with graft-versus-host disease (GVHD) who were receiving immunosuppressive therapy. The primary end point was the incidence of proven or probable invasive fungal infections from randomization to day 112 of the fixed treatment period of the study.Of a total of 600 patients, 301 were assigned to posaconazole and 299 to fluconazole. At the end of the fixed 112-day treatment period, posaconazole wa…

AdultMalePosaconazolemedicine.medical_specialtyAntifungal AgentsAdolescentmedicine.medical_treatmentGraft vs Host DiseaseKaplan-Meier EstimateHematopoietic stem cell transplantationOpportunistic InfectionsAspergillosisDouble-Blind MethodRisk FactorsInternal medicinemedicineClinical endpointAspergillosisHumansFluconazoleAgedbusiness.industryIncidence (epidemiology)Hematopoietic Stem Cell TransplantationGeneral MedicineMiddle AgedTriazolesmedicine.diseaseSurgeryTransplantationGraft-versus-host diseaseMycosesFemalebusinessFluconazolemedicine.drugNew England Journal of Medicine
researchProduct